Clinical Trials
Phase 2 trial reports 91% 5-year PFS with pembrolizumab-GVD in Hodgkin lymphoma
Patel et alBlood

A 5-year follow-up of a multicenter phase II trial (NCT03618550) evaluated the long-term efficacy and safety of pembrolizumab combined with gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The cohort comprised 39 enrolled patients, of whom 41% had primary refractory disease and 38% had experienced relapse within one year of initial treatment.
Patients received 21-day cycles consisting of pembrolizumab 200 mg IV on day 1, alongside gemcitabine 1,000 mg/m², vinorelbine 20 mg/m², and liposomal doxorubicin 15 mg/m² administered IV on days 1 and 8. Following up to four cycles of therapy, patients proceeded to high-dose chemotherapy and autologous stem cell rescue (HDT/ASCR).
Among 38 response-evaluable patients, the overall response rate was 100% and the complete response (CR) rate was 95%. Notably, 35 patients (92%) attained a CR after just two cycles of pembrolizumab-GVD, and 36 patients (95%) successfully underwent HDT/ASCR.
Over an extended median follow-up period of 57 months, only one patient developed disease recurrence after per-protocol treatment. Two deaths were recorded, both attributed to non-relapse or treatment-related causes. The estimated 5-year progression-free survival and overall survival rates were 91% and 94%, respectively. Extended follow-up revealed no new safety signals associated with the regimen.
Key Takeaways
- In response-evaluable patients with relapsed or refractory classical Hodgkin lymphoma, pembrolizumab-GVD achieved a 100% overall response rate and a 95% complete response rate, with 92% achieving complete response after only two cycles and 95% proceeding to autologous stem cell rescue.
- At a median follow-up of 57 months, estimated 5-year progression-free survival was 91% and overall survival was 94%, with one disease recurrence observed post-protocol therapy and no new safety signals reported.
